Kahn Swick & Foti notifies Capricor Therapeutics investors that they have until September 28, 2026 to apply for lead plaintiff in a securities class action. The lawsuit covers purchasers of Capricor securities between December 17, 2025 and July 26, 2026, alleging the company failed to disclose that its final statistical analysis plan for lead candidate Deramiocel was not submitted to the FDA before the biologics license application and was finalized one day before data unblinding. On July 27, 2026, after the FDA published briefing documents calling the analyses post-hoc and exploratory and questioning the drug's benefit-risk profile, Capricor's stock fell 64% to $7.00 per share. The case is pending in the United States District Court for the Southern District of California.
Capricor Therapeutics IncClass action alleges failure to disclose FDA submission issues; stock fell 64% after FDA briefing documents questioned Deramiocel.
SAP SE